THC's best-proven uses are narrow: easing chemotherapy nausea and stimulating appetite in illness-related wasting. Effects on multiple sclerosis stiffness and nerve pain are modest and often outweighed by side effects. Benefits for sleep or stress fade with regular use. Consistent risks include impaired thinking, dependence, and, in vulnerable people, anxiety and psychosis. (Full Review)

Protocol

Standard Dosing

2.5 mg, 1–3×/day

Dronabinol started low and titrated upward as tolerated; lowest effective dose to limit intoxication.

Dosing Pattern

Split, smaller doses

Split daily doses preferred over a single large dose to maintain effect while limiting peak intoxication.

Best Time of Day

Evening

Timed to evening or periods when alertness is not required; appetite/antiemetic dosing timed to meals.

Time to effect

Oral Forms

1–4 hours to peak

Must be converted in the liver; impatient re-dosing is a common cause of overconsumption.

Inhaled

Within minutes

Inhaled THC acts within minutes of use.

Benefits

High: Chemotherapy-induced nausea and vomiting relief; appetite stimulation in wasting conditions

Medium: Muscle stiffness relief in multiple sclerosis; chronic neuropathic pain reduction

Low: Sleep onset facilitation; Tourette syndrome tic reduction

Speculative: Neuroprotection and anti-inflammatory effects; glaucoma eye-pressure reduction

Contraindications

Personal or family history of psychosis or schizophrenia

Pregnant or breastfeeding individuals

Recent heart attack (<90 days), unstable angina, or NYHA Class III–IV heart failure

Adolescents and young adults (developing brain)

Prior cannabis use disorder

Key Interactions

CNS depressants (benzodiazepines such as diazepam, opioids such as oxycodone, alcohol)

CYP2C9 and CYP3A4 inhibitors (azole antifungals such as ketoconazole, certain HIV drugs such as ritonavir, grapefruit juice)

CYP enzyme inducers (rifampin, carbamazepine, St. John's wort)

OTC sedating antihistamines (diphenhydramine) and sleep aids

Blood thinners (warfarin)

Supplements with sedative or blood-pressure-lowering effects (melatonin, valerian, kava, high-dose magnesium)

Risk & Side Effects

High: Acute cognitive and psychomotor impairment; dizziness, sedation, and related adverse events; dependence and cannabis use disorder

Medium: Psychiatric effects: anxiety, paranoia, and psychosis; cardiovascular strain

Low: Cannabinoid hyperemesis syndrome; respiratory irritation from smoked forms

Speculative: Effects on the developing and aging brain; reproductive and hormonal effects

Monitoring

Marker	Target	Why
Resting heart rate	50–70 bpm	THC raises heart rate; flags cardiovascular strain
Blood pressure (seated and standing)	~110–125 / 70–80 mmHg	Detects THC-related blood-pressure swings and drops on standing
Liver enzymes (ALT, AST)	ALT/AST <25 U/L	THC is liver-metabolized; screens for impaired clearance
Mental-health screen (anxiety/psychosis)	No active or worsening symptoms	THC can trigger anxiety, paranoia, or psychosis
Fasting glucose	70–90 mg/dL	THC affects appetite and metabolism; tracks metabolic impact
CBC (complete blood count)	Within normal limits	General safety screen with chronic use

Cadence: Baseline before the first dose; at 2–4 weeks after starting or any dose increase; then every 6–12 months with regular use.

Qualitative Assessment

Sleep quality and morning grogginess
Daytime alertness, memory, and concentration
Mood, anxiety level, and any paranoia
Appetite and unintended weight change
Signs of tolerance, craving, or escalating use

THC for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment